Ki16425 CAS: 355025-24-0
MF: C23H23ClN2O5S
MW: 475.0
A competitive inhibitor of EDG-2, EDG-4, and EDG-7.
  1. Home
  2. Chemicals
  3. Protein-Interacting Inhibitors, Activators & Substrates
  4. Protein Inhibitors
  5. EDG-2 Inhibitors
  6. Ki16425

Ki16425 (CAS 355025-24-0)

Ki16425 | CAS 355025-24-0 is rated 5.0 out of 5 by 1.
  • y_2021, m_4, d_19, h_17
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.14
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_221788, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 142ms
  • REVIEWS, PRODUCT
5.0(1)
Write a review Ask a question
5
1
4
0
3
0
2
0
1
0
See product citations (15)
Alternate Names: 3-[[[4-[4-[[[1-(2-Chlorophenyl)ethoxy]carbonyl]amino]-3-methyl-5-isoxazolyl]phenyl]methyl]thio]propanoic acid
Application: Ki16425 is a competitive inhibitor of EDG-2, EDG-4, and EDG-7
CAS Number: 355025-24-0
Purity: ≥95%
Molecular Weight: 475.0
Molecular Formula: C23H23ClN2O5S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data (including water content).

QUICK LINKS

Click on image or enlarge button to enlarge

Ki16425 is a competitive, potent, and reversible inhibitor of EDG-2 (Ki = 0.34 μM), EDG-4 (Ki = 6.5 μM), and EDG-7 (Ki = 0.93 μM).


References

1. Ohta, H., et al. 2003. Mol. Pharmacol. 64: 994-1005. PMID: 14500756
2. Yamada, T., et al. 2004. J. Biol. Chem. 279: 6595-6605. PMID: 14660630
3. Choi, J.W., et al. 2008. Biochim. Biophys. Acta. 1781: 531-539. PMID: 18407842

Appearance :
Powder
Physical State :
Solid
Solubility :
Soluble in ethanol (95 mg/ml at 25° C), DMSO (95 mg/ml at 25° C), DMF (~10 mg/ml), 1: 4 solution of DMSO: PBS (pH 7.2) (~0.2 mg/ml), and water (<1 mg/ml at 25° C).
Storage :
Store at -20° C
Melting Point :
59.5-60.5° C
Boiling Point :
623.7° C at 760 mmHg (Predicted)
Density :
1.35 g/cm3 (Predicted)
Refractive Index :
n20D 1.63 (Predicted)
IC50 :
EDG-2: IC50 = 46 nM (human); EDG-7: IC50 = 301 nM (human)
Ki Data :
EDG-7: Ki= 148 nM (human); EDG-2: Ki= 0.17 µM (THP-1 fibroblasts); EDG-2: Ki= 0.34 µM (human); EDG-4: Ki= 0.54 µM (3T3 fibroblasts); EDG-4: Ki= 6.5 µM (human)
pK Values :
pKa: 4.32 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
WGK Germany :
3
PubChem CID :
10367662
MDL Number :
MFCD06798341
SMILES :
CC1=NOC(=C1NC(=O)OC(C)C2=CC=CC=C2Cl)C3=CC=C(C=C3)CSCCC(=O)O

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

Ki16425 (CAS 355025-24-0)  Product Citations

See how others have used Ki16425 (CAS 355025-24-0). Click on the entry to view the PubMed entry .

Citations 1 to 10 of 15 total

PMID: # 30840161  Olianas, MC.|Dedoni, S.|Onali, P.| et al. 2019. Apoptosis.

PMID: # 31017922  Konno, T.|Kotani, T.|Setiawan, J.|Nishigaito, Y.|Sawada, N.|Imada, S.|Saito, Y.|Murata, Y.|Matozaki, T.| et al. 2019. PLoS ONE. 14: e0215255.

PMID: # 29856906  Zhang, R.|Wang, J.| et al. 2018. Cancer Sci. 109: 2446-2457.

PMID: # 30181697  Nam, JS.|Sharma, AR.|Nguyen, LT.|Jagga, S.|Lee, YH.|Sharma, G.|Lee, SS.| et al. 2018. Korean J. Physiol. Pharmacol. 22: 503-511.

PMID: # 27605627  Olianas, MC. et al. 2016. J. Pharmacol. Exp. Ther. 359: 340-353.

PMID: # 26740622  Kedziora, KM. et al. 2016. J. Biol. Chem. 291: 4323-33.

PMID: # 25959255  Ohashi, T. et al. 2015. Exp. Dermatol. 24: 698-702.

PMID: # 25888927  Olianas, M.C. et al. 2015. Biochemical pharmacology. 95: 311-23.

PMID: # 24928086  Brusevold, IJ. et al. 2014. BMC Cancer. 14: 432.

PMID: # 27500235  Transplant Direct. e35.

Citations 1 to 10 of 15 total

What is the appearance of the compound?

Asked by: two2igm05
Thank you for your question. The appearance of Ki16425, sc-221788, is an off-white powder.
Answered by: TechService7
Date published: 2017-01-03
  • y_2021, m_4, d_19, h_17CST
  • bvseo_bulk, prod_bvqa, vn_bulk_3.0.14
  • cp_1, bvpage1
  • co_hasquestionsanswers, tq_1
  • loc_en_US, sid_221788, prod, sort_[SortEntry(order=LAST_APPROVED_ANSWER_SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 130ms
  • QUESTIONS, PRODUCT
Rated 5 out of 5 by from Zhao Zhao, J. et al. (PubMed 25701366) found that the lysophosphatidic acid receptor 1 antagonist Ki16425 blunts abdominal and systemic inflammation in a mouse model of peritoneal sepsis. -SCBT Publication Review
Date published: 2015-05-01
  • y_2021, m_4, d_19, h_17
  • bvseo_bulk, prod_bvrr, vn_bulk_3.0.14
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_1
  • loc_en_US, sid_221788, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 13ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2021 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.